Search results
Results from the WOW.Com Content Network
The high-affinity choline transporter (ChT) also known as solute carrier family 5 member 7 is a protein in humans that is encoded by the SLC5A7 gene. [5] It is a cell membrane transporter and carries choline into acetylcholine -synthesizing neurons .
Continuity of Care Document - The Continuity of Care Document (CCD) represents a core data set of the most relevant administrative, demographic, and clinical information facts about a patient's healthcare, covering one or more healthcare encounters. The primary use case for the CCD is to provide a snapshot in time containing the germane ...
Canada Health Transfer payments by year since FY2005. Unlike Equalization payments, which are unconditional, the CHT is a block transfer; the funds must be used by provinces and territories for the purposes of "maintaining the national criteria" for publicly provided health care in Canada (as set out in the Canada Health Act).
Inspection and conformity assessment of Good Clinical Practice (GCP), Good Laboratory Practice (GLP), and Good Practice Systems and Programs (GPSP) Auditing of manufacturers to ensure they conform to Good Manufacturing Practice (GMP) and have a suitable Quality Management System (QMS) Post-marketing drug safety: [citation needed]
One of the earliest ePRO studies used a LINC-2 minicomputer to collect patient data. The majority of patients preferred the computer to paper data collection. [7] Similar findings have been reported from many later studies. [8] [9] Elderly patients, and those not familiar with computers, might be expected to have more problems.
The new tariffs were set to take place at 12:01 a.m. on Tuesday, but were paused for at least 30 days after Canada made concessions to President Trump Monday — just as Mexico had done less than ...
Progressive supranuclear palsy (PSP) is a late-onset neurodegenerative disease involving the gradual deterioration and death of specific volumes of the brain. [1] [2] The condition leads to symptoms including loss of balance, slowing of movement, difficulty moving the eyes, and cognitive impairment. [1]
Choline acetyltransferase was first described by David Nachmansohn and A. L. Machado in 1943. [6] A German biochemist, Nachmansohn had been studying the process of nerve impulse conduction and utilization of energy-yielding chemical reactions in cells, expanding upon the works of Nobel laureates Otto Warburg and Otto Meyerhof on fermentation, glycolysis, and muscle contraction.